Officials at eXoZymes, which focuses on cell-free manufacturing and the development of AI-enhanced “exozymes,” say that an independent partner, Cayman Chemicals, ran eXoZymes’ technology at pilot scale and achieved results consistent with, and in some cases exceeding, earlier internal runs.
